As the cost of bringing a new medicine to market is now counted in billions of dollars and the number of NDA’s submitted is at best stagnant year on year, we must ask ourselves what is wrong with the drug development process and how can it be fixed. As the FDA document Innovation or Stagnation Challenge and Opportunity on the Critical Path to New Medical Products put it :
